계명대학교 의학도서관 Repository

Analysis of the Cancer Genome Atlas Data to Determine the Prognostic Value of GABPB1L and TERT in Glioblastoma

Metadata Downloads
Affiliated Author(s)
이재호
Alternative Author(s)
Lee, Jae Ho
Journal Title
Keimyung Med J
Issued Date
2021
Keyword
GABPB1LGlioblastomaTCGATERT
Abstract
Glioblastoma multiforme (GBM) is the most lethal type of brain tumor and its prognosis was extremely poor. Here, we studied the clinical and prognostic value of telomerase reverse transcriptase (TERT) and GA Binding Protein Transcription Factor Subunit Beta 1 longer (GABPB1L) mRNA expression in GBM by using open big data. In total 152 GBM patients, gene expressions were downloaded from the Cancer Genome Atlas (TCGA) data and its values were statistically analyzed. TCGA data showed that GABPB1L mRNA expression levels did not correlate with those of TERT mRNA (r = -0.027, p = 0.744). GABPB1L and TERT expressions in GBM were associated with subtype by gene expression. GABPB1L (562.7 ± 76.8 days vs. 479.1 ± 5.8 days, p = 0.401) and TERT (468.1 ± 43.6 days vs. 565.3 ± 75.8 days, p = 0.403) expression was not associated with GBM prognosis. However, disease-free survival was tended to be different in GBM patients according to TERT and GABPB1L expressions though it did not get statistical significance (2122.6 ± 160.2 days vs. 1381.1 ± 244.0 days, p = 0.072). These genes may contribute to the GBM pathogenesis and its further study should be performed in GBM patients and cell lines.
Department
Dept. of Anatomy (해부학)
Citation
김종완. (2021). Analysis of the Cancer Genome Atlas Data to Determine the Prognostic Value of GABPB1L and TERT in Glioblastoma. Keimyung Med J, 40(2), 73-76. doi: 10.46308/kmj.2021.00171
Type
Journal
DOI
10.46308/kmj.2021.00171
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/43895
Appears in Collections:
2. Keimyung Medical Journal (계명의대 학술지) > 2021
1. School of Medicine (의과대학) > Dept. of Anatomy (해부학)
Authorize & License
  • AuthorizeOpen
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.